
In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.
Researchers have developed an algorithm that uses traditional risk factors to predict whether a newborn will develop obesity as a child.






